For example, the extensive characterization of activating SHP2 mutants, including the high-frequency cancer mutation E76K, revealed key features of the N-SH2/PTP auto-inhibitory interface and also yielded the first active-state structure of SHP220,21. This evidence concerns the gene PTPN11 and cancer.